FDA adcomm votes 11-2 to expand Roche's Polivy label in DLBCL

An FDA committee of outside cancer experts voted 11-2 Thursday that the FDA should expand Roche’s Polivy label to include it as a treatment in combo with rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP) for the treatment of adult patients with previously untreated diffuse large B-cell lymphoma (DLBCL).